{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:13:10Z","timestamp":1778937190398,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objectives are to determine the frequency that skin color is reported in randomized controlled trials (RCTs) involving squamous cell carcinoma (SCC) detection and treatment in leading dermatology journals. A systematic review of RCTs involving SCC was conducted among the top ten most impactful dermatology journals from inception to July 10th, 2023. Studies were included if they reviewed the treatment, prevention, or detection of SCC, involved patients directly and were classified as traditional RCTs. Studies were considered positive for reporting SOC if there was any demographic data in the methods or results of the following terms: Fitzpatrick scale, race, ethnicity, sunburn tendency, or skin of color. Of the 39 studies which were identified, 23 reported data related to skin color data (59.0%). White individuals were the most reported in these studies (56.5%). Subgroup analysis was conducted, and no statistical significance was found for study location, year of publication, or funding source. Skin color impacts skin cancer detection, predominant location of tumors, and recurrence. Less than 60% of high-quality RCTs related to SCC in top global dermatology journals included skin color among the demographic traits of study participants. Subgroup analysis demonstrated no improvement in reporting over the past 2 decades. Further research is needed to understand the reason for low skin color reporting rates among SCC-related RCTs and the impact this has on society.<\/jats:p>","DOI":"10.1007\/s00403-024-02843-2","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T11:01:33Z","timestamp":1711796493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Skin color reporting in squamous cell carcinoma-related randomized controlled trials in top dermatology journals: a systematic review"],"prefix":"10.1007","volume":"316","author":[{"given":"Natasha L.","family":"Salmen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klarens","family":"Menage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony N.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deven P.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Brodell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"issue":"1","key":"2843_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hoc.2018.08.001","volume":"33","author":"A Waldman","year":"2019","unstructured":"Waldman A, Schmults C (2019) Cutaneous squamous cell carcinoma. Hematol Oncol Clin North Am 33(1):1\u201312. https:\/\/doi.org\/10.1016\/j.hoc.2018.08.001","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"2843_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","volume":"68","author":"PS Karia","year":"2013","unstructured":"Karia PS, Han J, Schmults CD (2013) Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 68(6):957\u2013966","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"2843_CR3","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1001\/jama.1989.03430150065027","volume":"262","author":"AG Glass","year":"1989","unstructured":"Glass AG, Hoover RN (1989) The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 262(15):2097\u20132100","journal-title":"JAMA"},{"key":"2843_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1146\/annurev-pathol-042320-120056","volume":"17","author":"MS Chang","year":"2022","unstructured":"Chang MS, Azin M, Demehri S (2022) Cutaneous squamous cell carcinoma: the frontier of cancer immunoprevention. Annu Rev Pathol 17:101\u2013119","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"2843_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/ijd.12553","volume":"54","author":"JR Kallini","year":"2015","unstructured":"Kallini JR, Hamed N, Khachemoune A (2015) Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends. Int J Dermatol 54(2):130\u2013140","journal-title":"Int J Dermatol"},{"issue":"3","key":"2843_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1751-1097.2007.00226.x","volume":"84","author":"M Brenner","year":"2008","unstructured":"Brenner M, Hearing VJ (2008) The protective role of melanin against UV damage in human skin. Photochem Photobiol 84(3):539\u2013549","journal-title":"Photochem Photobiol"},{"issue":"4","key":"2843_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.det.2019.05.009","volume":"37","author":"L Hogue","year":"2019","unstructured":"Hogue L, Harvey VM (2019) Basal cell carcinoma, squamous cell carcinoma, and cutaneous melanoma in skin of color patients. Dermatol Clin 37(4):519\u2013526. https:\/\/doi.org\/10.1016\/j.det.2019.05.009","journal-title":"Dermatol Clin"},{"key":"2843_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jaad.2005.08.063","volume":"55","author":"HM Gloster","year":"2006","unstructured":"Gloster HM, Neal K (2006) Skin cancer in skin of color. J Am Acad Dermatol 55:741\u2013760 [quiz: 761\u20134]","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2843_CR9","first-page":"170","volume":"21","author":"PT Bradford","year":"2009","unstructured":"Bradford PT (2009) Skin cancer in skin of color. Dermatol Nurs 21(4):170\u2013178","journal-title":"Dermatol Nurs"},{"issue":"6","key":"2843_CR10","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/jid.2013.35","volume":"133","author":"MY Xiong","year":"2013","unstructured":"Xiong MY, Rizzo AE, Cohen TSD, Dyer RK, Korgavkar K, Bingham SF, Weinstock MA, for the Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial Group (2013) Predictors of squamous cell carcinoma in high-risk patients in the VATTC trial. J Invest Dermatol 133(6):1521\u20131532. https:\/\/doi.org\/10.1038\/jid.2013.35","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2843_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","volume":"146","author":"JK Rivers","year":"2002","unstructured":"Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y (2002) Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 146(1):94\u2013100","journal-title":"Br J Dermatol"},{"issue":"6","key":"2843_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.abd.2019.10.004","volume":"94","author":"CPH Reinehr","year":"2019","unstructured":"Reinehr CPH, Bakos RM (2019) Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects. An Bras Dermatol 94(6):637\u2013657","journal-title":"An Bras Dermatol"},{"key":"2843_CR13","unstructured":"U.S. Census Bureau quickfacts: United States. United States Census Bureau. (n.d.). https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045222"},{"issue":"12","key":"2843_CR14","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.22034\/APJCP.2016.17.12.5257","volume":"17","author":"AK Gupta","year":"2016","unstructured":"Gupta AK, Bharadwaj M, Mehrotra R (2016) Skin cancer concerns in people of color: risk factors and prevention. Asian Pac J Cancer Prev 17(12):5257\u20135264. https:\/\/doi.org\/10.22034\/APJCP.2016.17.12.5257","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"2843_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jaad.2023.04.011","volume":"89","author":"J Mineroff","year":"2023","unstructured":"Mineroff J, Nguyen JK, Jagdeo J (2023) Racial and ethnic underrepresentation in dermatology clinical trials. J Am Acad Dermatol 89(2):293\u2013300. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.011","journal-title":"J Am Acad Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-02843-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T13:05:19Z","timestamp":1712667919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-02843-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["2843"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-02843-2","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]},"assertion":[{"value":"27 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Robert Brodell, M.D. discloses the following potential conflicts of interest: Advisory boards: Novan and Amgen.  Research funding: Pfizer, Novartis, and Sanofi. Stock: Veragen, Inc.  Natasha Salmen, Klarens Menage, Anthony Baumann, and Deven Curtis have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"115"}}